EcoDrugPlus

Dna Methyltransferase 1

Ensembl ID : ENSPNYG00000013676
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSPNYG00000018784
Gene Symbol: LOC102209881
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase 2-Alpha-Like

Ensembl ID : ENSPNYG00000018347
Gene Symbol: LOC102216068
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSPNYG00000001351
Gene Symbol: TOP1
1 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSPNYG00000001066
Gene Symbol: TOP2B
3 Cross references
207 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSPNYG00000005837
Gene Symbol: EML4
3 Cross references
207 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSPNYG00000016413
Gene Symbol: EPHA3
3 Cross references
210 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSPNYG00000024223
Gene Symbol: F2RL3
3 Cross references
195 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSPNYG00000002068
Gene Symbol: FAU
3 Cross references
300 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSPNYG00000010964
Gene Symbol: FYN
3 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSPNYG00000012868
Gene Symbol: GPR119
4 Cross references
174 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSPNYG00000008185
Gene Symbol: HCK
3 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).